Navigation Links
Scott & White Healthcare researcher finds success with new anti-cancer drug
Date:12/22/2009

A study conducted at Scott & White Healthcare in Temple, Texas, found that a new drug stopped the growth of breast tumors in mice. This drug is unique in that it works both by stopping the cancer cells from growing and metastasizing to other organs, and by stimulating the immune system to destroy breast cancer cells and keeps them from coming back. This is the only drug that's able to work in both ways, while all other treatments work in one way or another. And, this research initiative not only involves physicians and biologists working together to bring treatments from the laboratory to the bedside, but a unique third component agriculturalists.

Researcher Alexzander Asea, Ph.D., the Effie and Wofford Cain Endowed Chair in Clinical Pathology, and division chief of investigative pathology at Scott & White Healthcare and the Texas A&M Health Science Center, said "we found that some of the mice were essentially cured."

"All anti-cancer drugs broadly fall into two categories; either directly killing cancer cells (often healthy cells as well), or vaccines that help sick patients by boosting the immune system to better fight off cancer. This new drug works both ways, as a vaccine by taking away the cancer cell ability to grow, multiply and spread to distant organs, and by educating the immune system to recognize the breast cancer cells as 'foreign invaders' that need to be attacked and destroyed and to continue that process over time," Dr. Asea said.

Dr. Asea went on to say "breast cancer cells fly under the radar of the immune system, by turning off the machinery that normally puts recognition structures on the surface of cancer cells which the immune system uses to recognize and destroy them. To overcome this problem, this injectable drug turns on this machinery within the cancer cells allowing the immune system to recognize the cancer cells and kill them. The unique thing is that the revved-up immune cells will continue patrolling for any hidden cancer cells months and years after the last cancer cells have been killed," Dr. Asea said.

"Collaborating with the agricultural community on this research also allows us to use a special delivery mechanism of the drug that doesn't cause the negative side effects you see with more traditional treatments like chemotherapeutic agents," explained Dr. Asea.

Dr. Asea said only about one year of additional work is required before Phase I clinical trials can begin in women with metastatic breast cancer at Scott & White Hospital. "However, this stage requires a significant amount of funding. We're currently looking at various sources including federal, state and private sources to get this promising drug to the patients who need it."


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related biology news :

1. American Society for Microbiology honors D. Scott Merrell
2. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
3. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
4. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
5. Wolf reintroduction proposed in Scottish Highland test case
6. Scott & White Healthcare researcher finds success with new anti-cancer drug
7. ESA honored at White House ceremony
8. Unveiling the underwater ways of the white shark
9. New whitepaper offers options for university implementation of NIH policy
10. Clumps of red and white blood cells may contribute to sickle cell disease
11. White House science office needs upgrade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/19/2016)... 19 de diciembre de 2016  Mosaic Biomedicals SL anunció hoy ... de MSC-1, un anticuerpo humanizado que se espera comenzar a utilizar ... múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el primer ... leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos tumores ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ANNAPOLIS, Md. and GAITHERSBURG, ... Inc. (NYSE MKT: PIP) and Altimmune, Inc., a ... the signing of a definitive agreement for the ... transaction. Altimmune,s current investors include Novartis Venture Fund, ... company will be a fully-integrated and diversified immunotherapeutics ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... engineers, and scientists from around the world, was today awarded the "Best Science ... is based entirely on merit and decided upon by a dedicated team of ...
(Date:1/19/2017)... -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. ... and inoperable solid tumor cancers, announced today that Dr. ... Bio, will present at the Phacilitate Immunotherapy World Conference ... Hotel in Miami, Florida . ... Therapeutic Approaches – Expanding the Reach of Cancer Immunotherapy ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 According to ... Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, ... market is expected to reach USD 739.9 Million by 2021 from USD 557.1 ... Continue Reading ... MarketsandMarkets Logo ...
Breaking Biology Technology: